Hepatitis Monthly

Published by: Kowsar

Rapid Virological Response Represents the Highest Prediction Factor of Response to Antiviral Treatment in HCV-Related Chronic Hepatitis: a Multicenter Retrospective Study

Alessandro Federico 1 , * , Mario Masarone 2 , Marco Romano 1 , Marcello Dallio 1 , Valerio Rosato 3 and Marcello Persico 2
Authors Information
1 Department of Clinical and Experimental Medicine, Division of Hepatogastroenterology, Second University of Naples, Naples, Italy
2 Department of Internal Medicine and Hepatology, Internal Medicine and Hepatology Unit, University of Salerno, Salerno, Italy
3 IV Division of Internal Medicine and Hepatology, Second University of Naples, Naples, Italy
Article information
  • Hepatitis Monthly: June 01, 2015, 15 (6); e18640
  • Published Online: June 23, 2015
  • Article Type: Research Article
  • Received: February 28, 2014
  • Revised: May 26, 2014
  • Accepted: June 22, 2014
  • DOI: 10.5812/hepatmon.15(6)2015.18640

To Cite: Federico A, Masarone M, Romano M, Dallio M, Rosato V, et al. Rapid Virological Response Represents the Highest Prediction Factor of Response to Antiviral Treatment in HCV-Related Chronic Hepatitis: a Multicenter Retrospective Study, Hepat Mon. 2015 ; 15(6):e18640. doi: 10.5812/hepatmon.15(6)2015.18640.

Abstract
Copyright © 2015, Kowsar Corp. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Objectives
3. Patients and Methods
4. Results
5. Discussion
Acknowledgements
References
  • 1. Lauer GM, Walker BD. Hepatitis C virus infection. N Engl J Med. 2001; 345(1): 41-52[DOI][PubMed]
  • 2. Koike K. Antiviral treatment of hepatitis C: present status and future prospects. J Infect Chemother. 2006; 12(5): 227-32[DOI][PubMed]
  • 3. Mangia A, Gentile R, Cascavilla I, Margaglione M, Villani MR, Stella F, et al. HLA class II favors clearance of HCV infection and progression of the chronic liver damage. J Hepatol. 1999; 30(6): 984-9[PubMed]
  • 4. Del Campo JA, Romero-Gomez M. Steatosis and insulin resistance in hepatitis C: a way out for the virus? World J Gastroenterol. 2009; 15(40): 5014-9[PubMed]
  • 5. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FJ, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med. 2002; 347(13): 975-82[DOI][PubMed]
  • 6. Zeuzem S, Buti M, Ferenci P, Sperl J, Horsmans Y, Cianciara J, et al. Efficacy of 24 weeks treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia. J Hepatol. 2006; 44(1): 97-103[DOI][PubMed]
  • 7. Kau A, Vermehren J, Sarrazin C. Treatment predictors of a sustained virologic response in hepatitis B and C. J Hepatol. 2008; 49(4): 634-51[DOI][PubMed]
  • 8. Berg T, Carosi G. Optimizing outcomes in patients with hepatitis C virus genotype 2 or 3. Antivir Ther. 2008; 13 Suppl 1: 17-22[PubMed]
  • 9. Lee SS, Ferenci P. Optimizing outcomes in patients with hepatitis C virus genotype 1 or 4. Antivir Ther. 2008; 13 Suppl 1: 9-16[PubMed]
  • 10. Hadziyannis SJ, Sette HJ, Morgan TR, Balan V, Diago M, Marcellin P, et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med. 2004; 140(5): 346-55[PubMed]
  • 11. National Institutes of H. National Institutes of Health Consensus Development Conference Statement: Management of hepatitis C: 2002--June 10-12, 2002. Hepatology. 2002; 36(5 Suppl 1)-20[DOI][PubMed]
  • 12. Reid MC, Guo Z, Van Ness PH, O'Connor PG, Concato J. Are commonly ordered lab tests useful screens for alcohol disorders in older male veterans receiving primary care&#63. Subst Abus. 2005; 26(2): 25-32[PubMed]
  • 13. American Diabetes A. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2006; 29 Suppl 1-8[PubMed]
  • 14. Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation. 2005; 112(17): 2735-52[DOI][PubMed]
  • 15. Ishak K, Baptista A, Bianchi L, Callea F, De Groote J, Gudat F, et al. Histological grading and staging of chronic hepatitis. J Hepatol. 1995; 22(6): 696-9[DOI]
  • 16. Brunt EM. Nonalcoholic steatohepatitis. Semin Liver Dis. 2004; 24(1): 3-20[DOI][PubMed]
  • 17. Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem. 1987; 162(1): 156-9[DOI][PubMed]
  • 18. Kwok S, Higuchi R. Avoiding false positives with PCR. Nature. 1989; 339(6221): 237-8[DOI][PubMed]
  • 19. Viazov S, Zibert A, Ramakrishnan K, Widell A, Cavicchini A, Schreier E, et al. Typing of hepatitis C virus isolates by DNA enzyme immunoassay. J Virol Methods. 1994; 48(1): 81-91[PubMed]
  • 20. Arase Y, Suzuki F, Sezaki H, Suzuki Y, Kawamura Y, Kobayashi M, et al. Suitable treatment period in patients with virological response during combination therapy of peginterferon and ribavirin for chronic hepatitis C. Intern Med. 2008; 47(14): 1301-7[PubMed]
  • 21. Zuberi BF, Zuberi FF, Memon SA, Qureshi MH, Ali SZ, Afsar S. Sustained virological response based on rapid virological response in genotype-3 chronic hepatitis C treated with standard interferon in the Pakistani population. World J Gastroenterol. 2008; 14(14): 2218-21[PubMed]
  • 22. Andriulli A, Mangia A, Iacobellis A, Ippolito A, Leandro G, Zeuzem S. Meta-analysis: the outcome of anti-viral therapy in HCV genotype 2 and genotype 3 infected patients with chronic hepatitis. Aliment Pharmacol Ther. 2008; 28(4): 397-404[DOI][PubMed]
  • 23. Petta S, Craxi A. How to optimize HCV therapy in genotype 1 patients: predictors of response. Liver Int. 2013; 33 Suppl 1: 23-9[DOI][PubMed]
  • 24. Toyoda H, Kumada T, Shimada N, Takaguchi K, Ide T, Sata M, et al. Significance of a reduction in HCV RNA levels at 4 and 12 weeks in patients infected with HCV genotype 1b for the prediction of the outcome of combination therapy with peginterferon and ribavirin. BMC Infect Dis. 2012; 12: 324[DOI][PubMed]
  • 25. Petta S, Bellia C, Mazzola A, Cabibi D, Camma C, Caruso A, et al. Methylenetetrahydrofolate reductase homozygosis and low-density lipoproteins in patients with genotype 1 chronic hepatitis C. J Viral Hepat. 2012; 19(7): 465-72[DOI][PubMed]
  • 26. Petta S, Craxi A. Therapeutic algorithms for chronic hepatitis C in the DAA era during the current economic crisis: whom to treat? How to treat? When to treat? BMC Infect Dis. 2012; 12 Suppl 2[DOI][PubMed]
  • 27. Lange CM, Zeuzem S. Perspectives and challenges of interferon-free therapy for chronic hepatitis C. J Hepatol. 2013; 58(3): 583-92[DOI][PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:

Author(s):

Article(s):

Create Citiation Alert
via Google Reader

Readers' Comments